Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 601

Results For "ED"

9539 News Found

Parliament passes National Nursing and Midwifery Commission (NNMC) Bill, 2023
Policy | August 09, 2023

Parliament passes National Nursing and Midwifery Commission (NNMC) Bill, 2023

Several crucial provisions to elevate the standards of nursing education and services, enhance professional conduct, and ensure greater transparency and accountability introduced


Altana acquires ultrasound metrology company Imaginant
News | August 09, 2023

Altana acquires ultrasound metrology company Imaginant

Imaginant offers a unique measurement capability through its PELT coating thickness gauges


Mandaviya addresses BRICS Health Minister’s meeting
News | August 09, 2023

Mandaviya addresses BRICS Health Minister’s meeting

Reiterates India’s commitment to the BRICS TB Research Network Initiative


Brenntag partners with Qualifyze to enhance pharma audit offering
News | August 09, 2023

Brenntag partners with Qualifyze to enhance pharma audit offering

Qualifyze specializes in Good Practice audits (GxP) audits and covers a wide range of areas, including excipients, starting materials, packaging, sustainability


Govt. passes National Dental Commission Bill, 2023
Policy | August 09, 2023

Govt. passes National Dental Commission Bill, 2023

The National Dental Commission Act 2023, will introduce a groundbreaking regulatory framework by establishing the National Dental Commission


Surging demand for Korean pharma in 2023 ahead of CPHI Korea
News | August 08, 2023

Surging demand for Korean pharma in 2023 ahead of CPHI Korea

Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings


Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
Drug Approval | August 06, 2023

Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023


Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations
Drug Approval | August 05, 2023

Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations

The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023


USFDA approves Merck’s ERVEBO for use in children 12 months of age and older
Drug Approval | August 05, 2023

USFDA approves Merck’s ERVEBO for use in children 12 months of age and older

Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease